{"Q": 1, "answer": "no", "rationale": "The segment contains 'advantages', which is positive, not a risk adjective.", "method": "llm_batch", "batch_id": "batch_1_7316", "batch_size": 200, "batch_pos": 162, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment describes technological advantages but lacks Q2 cues.", "method": "llm_batch", "batch_id": "batch_2_17704", "batch_size": 200, "batch_pos": 115, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment describes advantages of a technology, not a moderate verb paired with significant scale or impact.", "method": "llm_batch", "batch_id": "batch_3_15520", "batch_size": 200, "batch_pos": 63, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_14360", "batch_size": 200, "batch_pos": 44, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "The segment reports advantages of technology without explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_18248", "batch_size": 200, "batch_pos": 38, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_17680", "batch_size": 200, "batch_pos": 4, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_14876", "batch_size": 200, "batch_pos": 197, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "The segment describes the advantages/capabilities of a technology ('offers advantages in efficacy, speed... scalability, and reliability'), without explicit calming.", "method": "llm_batch", "batch_id": "batch_8_16028", "batch_size": 200, "batch_pos": 36, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
